PureTech Health announced the initiation of a Phase 2a proof-of-concept clinical trial of LYT-300 in healthy volunteers using a validated clinical model of anxiety. LYT-300 is PureTech’s wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychiatric disorders, including anxiety disorders and postpartum depression, or PPD. LYT-300 is an oral prodrug of allopregnanolone that was developed using PureTech’s Glyph platform, which harnesses the body’s natural lipid absorption and transport process to enable the oral administration of certain therapeutics that otherwise cannot be administered orally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly